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Abstract
Monocytes in the circulation of normal individuals express two
receptors for the constant region of immunoglobulin, FcyRI
and FcyRII. In contrast, we have observed that AIDS mono-
cytes express significant levels of a third FcyR, Fc'yRIII
(CD16), which is normally associated with activation or matura-
tion of the monocyte population. By dual-fluorescence analysis
using a monoclonal antibody specific for FcyRIII (MAb 3G8),
38.5±3.2% of the LeuM3 (CD14)-positive monocytes in AIDS
patients were CD16 positive as compared to 10.4±1.0% for
healthy individuals (n = 29; P < 0.005). Furthermore, AIDS
monocytes expressed FcyRIII-specific mRNA which is ex-
pressed minimally or not at all in control monocytes. As a re-
cently identified inducer of FcyRIII expression on blood mono-
cytes, transforming growth factor-,8 (TGF-0) was found to be
elevated in the serum and/or plasma of AIDS patients. More-
over, incubation of normal monocytes with AIDS serum or
plasma induced CD16 expression which correlated with serum
TGF-ft levels (r = 0.74, P < 0.001) and was inhibited with a
neutralizing antibody to TGF-ft. Thus, the increased CD16 ex-
pression on peripheral blood monocytes in AIDS patients may
be the consequence ofelevated circulating levels ofthe polypep-
tide hormone TGF-ft. (J. Clin. Invest. 1991. 87:1773-1779.)
Key words: CD16, CD32, CD64 * human immunodeficiency
virus * immune suppression * maturation * mononuclear phago-
cytes
Introduction
Receptors for the Fc domain ofimmunoglobulin (Ig) comprise
a group of closely related membrane glycoproteins present on
many cells participating in host defense (1). FcyRI receptors
(CD64) are found primarily on monocytes and macrophages
and bind monomeric IgG with high affinity, whereas FcyRII
receptors (CDw32) are a polymorphic family of molecules ex-
pressed on monocytes, neutrophils, eosinophils, B cells, and
platelets and mediate uptake ofimmune complexes and opson-
ized particles (2-5). FcyRIII receptors (CD 16), which are ex-
pressed on several cell types (1, 3, 5), are expressed only on a
small percentage (- 10%) of circulating monocytes (6). How-
ever, this receptor appears as monocytes mature and differen-
tiate in culture, in tissues, and at inflammatory sites (7-9). This
class of receptor plays an important role in the clearance of
immune complexes and within inflammatory sites (7).
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Recently, Fc-yRIII, but not FcyRI or Fc'yRII, have been
implicated as possible sites of HIV-1 entry in mononuclear
phagocytes. HIV-1 infection-enhancing antibodies have been
identified in the sera of seropositive patients (10-12) and
FcyRIII antibodies inhibit the enhancement of HIV-infection
in vitro (10). Although these results suggest that FcyRIII on
monocyte/macrophages mediate antibody-dependent en-
hancement of HIV infectivity by a pathway distinct from the
CD4 molecule, it is not clear whether antibody enhancement
of HIV infection occurs in vivo (13). The lack of FcyRIII
would likely preclude this route of infection on circulating
monocytes. However, since blood monocytes in AIDS patients
have been shown by various criteria to express phenotypic and
functional changes characteristic of an activated or differen-
tiated population (14-20), the possibility existed that they
might also show increased expression of FcyRIII.
In the present study, we show that monocytes freshly iso-
lated from patients with AIDS and AIDS-related complex
(ARC)' express increased levels of FcyRIII on their cell sur-
faces as compared to normal controls. Moreover, a soluble fac-
tor in the serum and/or plasma ofHIV- I -infected individuals
induced expression of Fc-yRIII in vitro on peripheral blood
monocytes obtained from control individuals. This activity
could be blocked by neutralizing antibodies to transforming
growth factor-f (TGF-fl) and is consistent with previous in vi-
tro and in vivo studies demonstrating that TGF-ft up-regulates
CD16 on human monocytes (8, 9). The identification of ele-
vated circulating levels ofTGF-,B in AIDS patients and its asso-
ciation with upregulation of Fc-yRIII may provide insight into
the immunopathogenesis of AIDS.
Methods
Patients. This study included 22 males with AIDS and 7 asymptom-
atic, seropositive males. Ofthe patients with AIDS, I had only Kaposi's
sarcoma, 20 had one or more opportunistic infections, and 1 had Ka-
posi's sarcoma, opportunistic infections, and bacterial infections. No
patient was on immunomodulatory therapy at the time ofstudy. Con-
trol subjects included 22 healthy, seronegative adults.
Peripheral bloodsamples. Sera were prepared from nonheparinized
peripheral blood samples obtained from AIDS patients and control
subjects. Plasma and mononuclear leukocytes (MNL) were separated
from heparinized blood. The sera and plasma were centrifuged, ali-
quoted, and stored at -200C. MNL isolated by Ficoll-Paque sedimenta-
tion were washed and suspended in Dulbecco's modified Eagle's me-
dium (DME, Gibco Laboratories, Grand Island, NY) containing 50
ltg/ml gentamicin and 2 mM glutamine. Total MNL and separate
monocyte and lymphocyte numbers were determined by size and phe-
1. Abbreviations used in thispaper:ARC, AIDS-related complex; FMF,
fluorescence microfluorometry; MNL, mononuclear leukocytes; PE,
phycoerythrin; TGF-,#, transforming growth factor-#.
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notypic analysis. To obtain purified populations of normal monocytes
(> 95% LeuM3+), leukapheresis preparations from healthy control
subjects (National Institutes of Health Blood Bank) were separated by
counterflow centrifugal elutriation (21).
Labeling of cell surface antigens. For analysis using dual-fluores-
cence microfluorometry (FMF), single-cell suspensions (50 yd) ofMNL
or monocytes (10 X 106/ml) in phosphate-buffered saline (PBS) supple-
mented with 0.1% sodium azide and 2% fetal calf serum (FCS) were
incubated at 40C for 30 min with phycoerythrin (PE)- and fluorescein
isothiocyanate (FITC)-conjugated monoclonal antibodies. Human AB
serum (10%) was added to the cells 10 min before this incubation to
prevent nonspecific binding to Fc receptors. Monoclonal antibodies
included those directed against monocyte surface antigens, LeuM3,
Mo2, LeuM9, MY9, and HLA-DR; the T cell antigen, Leul; and the
NK antigen, NHK-l (Becton Dickinson, Mountain View, CA; and
Coulter Immunology, Hialeah, FL). FcyR-specific monoclonal anti-
bodies were 3G8 (FcyRIII, CD16), IV.3 (Fc-yRII, CDw32), and 32.2
(FcyRI, CD64) (Medarex Inc., Lebanon, NH) (3). Nonspecific fluores-
cence was evaluated with the relevant PE/FITC-conjugated IgG, and
IgG2 subclasses (Simultest, Becton Dickinson). After staining, the cells
were washed twice in buffer without FCS and immediately resus-
pended in 0.5 ml 2% paraformaldehyde and stored at 4°C until analysis
by FMF using a FACStarPLUS* flow cytometer (Becton-Dickinson)
with a single excitation source (200 mW argon ion laser) (8). An analy-
sis gate was set to include cells with the forward- and side-scatter char-
acteristics of monocytes.
Northern blot analysis of monocyte mRNA. Total RNA was ex-
tracted by a one-step acid guanidine thiocyanate phenol-chloroform
extraction method (22) from 5-10 x 106 monocytes obtained from
peripheral blood MNL ofpatients or normal individuals that had been
adhered for 1.5 h and washed to remove nonadherent cells. RNA (5 4g)
was electrophoresed in formaldehyde-containing agarose gels, trans-
ferred to nitrocellulose filters, and hybridized 18 h with a 32P-labeled
CD16 cDNA probe consisting of a 1-kb Xba I fragment of the pCD16
clone (kindly provided by Dr. Brian Seed, Massachusetts General Hos-
pital, Boston, MA) (23). The filters were then exposed to Kodak XAR-
5 film with intensifier screens at -70°C. The ethidium bromide stain-
ing pattern ofthe 28S and 18S ribosomal RNA bands indicated equiva-
lent amounts of RNA loaded in each lane, and hybridization to the
constitutively expressed He7 probe (24) served as the internal control.
Incubation of monocytes with serum and plasma. Purified mono-
cyte populations obtained from control subjects (> 95% LeuM3 posi-
tive) were suspended in DME (5 X 106/ml) with 0-20% serum or
plasma from patients and controls and cultured for 24 h at 37°C in 5%
CO2. After the incubation, monocytes were washed, incubated with
FITC-conjugated monoclonal antibodies, and analyzed by FMF. In
additional experiments, plasma samples (100 Ml) were preincubated 0.5
hr with a neutralizing antibody to TGF-,B1 (140 Mg; R & D Systems,
Minneapolis, MN) or with an equivalent concentration ofnonimmune
rabbit IgG (Sigma Chemical Co., St. Louis, MO) before addition to the
monocyte cultures.
Measurement of TGF-, bioactivity in AIDS plasma. TGF-,B was
quantitated by its ability to inhibit IL- -dependent thymocyte prolifer-
ation (25, 26). Serial dilutions of plasma in parallel with a purified
human platelet-derived TGF-#,B standard (Collaborative Research,
Boston, MA) were added to thymocytes from 4-8-wk-old female C3H/
HeJ mice in the presence of suboptimal concentrations of phytohe-
magglutinin (1 Mg/ml) (Burroughs Wellcome Co., Greenville, NC) and
IL-l at 100 U/ml (Genzyme Corp., Boston, MA). Before assay, plasma
samples were untreated or adjusted to pH . 3.0 with 6N HCl for 10-30
min, neutralized with 6 N NaOH/ I M Hepes, and diluted fourfold with
culture media (26). After 72 h, the thymocyte cultures were pulsed with
0.5 MCi per well tritiated thymidine (specific activity 1.9 Ci/mM;
Schwarz-Mann, Orangeburg, NY) and harvested, and incorporation of
tritiated thymidine was determined. TGF-# concentrations (ng/ml)
were determined by comparison to the TGF-,B standard curve in which
the TGF-# IC.o is - 0.05 ng/ml (26).
Statistical analysis. Results are presented as mean±SE. Statistical
significance was determined using Student's t test and P < 0.05 was
considered statistically significant. Correlations between two variables
were determined by Pearson's correlation coefficient.
Results
Fc'yRIII expression on circulating monocytes from AIDS pa-
tients. Freshly isolated MNL from individuals with AIDS and
normal subjects were incubated with FITC-conjugated MAb
3G8 in parallel with an FITC-IgG control. Fluorescence analy-
sis performed on monocytes electronically gated on the basis of
their light scatter patterns revealed a marked difference in the
number of MNL staining positive with FITC-3G8 (FcyRIII,
CD16'). As shown in Fig. 1, cells with the characteristics of
monocytes from three patients with AIDS (Al-3) expressed
substantial levels of cell surface CD 16. In contrast, minimal
numbers of monocytes from normal individuals (CJ-3) were
CD 1 6'. Parallel analysis of CD64 (FcyRI) and CDw32
(FcyRII) revealed no enhancement in the number of positive
cells nor in the density of staining (receptor number) between
AIDS and control monocytes. On the contrary, FcyRII, and
FcyRI in particular, often were reduced in number, rather than
enhanced (data not shown).
Dual-fluorescence analysis ofFc-yRIII and monocyte anti-
gens. Since FcyRIII are also found on neutrophils and natural
killer cells (27, 28), CD16' cells were further characterized by
dual-color fluorescence using a battery of monocyte-specific
PE-conjugated MAb (red) in combination with FITC-3G8
(green). The majority of cells expressing CD16 in the MNL
population co-expressed markers consistent with cells of the
monocytic lineage. Shown in Fig. 2 (top) are contour plots of
dual-color-labeled MNL from a representative AIDS patient.
In these populations, CD116+ cells co-expressed LeuM3,
LeuM9, MY9, Mo2, and CD64, all of which are monocyte
antigens. In a parallel dual-color analysis ofMNL from a repre-
sentative control subject (Fig. 2, bottom), the number of
CD16+ cells which co-stained with any of the monocyte spe-
cific antigens never exceeded 10% ofthe population. For exam-
ple, all of the cells in the patient population that expressed
CD16+ (MAb 3G8) were also positive for CD64 (MAb 32.2),
which is found only on monocytes and macrophages, whereas
the comparable CD64+ population of the control subject was
< 3% CD 1 6+. A similar pattern was observed for the co-expres-
sion of a battery of additional monocyte-specific markers (Fig.
2). Although NKH-1+ cells also express CD 16, contamination
with these cells was routinely < 10% and, moreover, these cells
did not co-express monocyte-specific antigens. Additionally,
the CD16+, CD14+ cells exhibited morphology, phagocytic ac-
tivity, and superoxide anion production consistent with cells of
monocytic lineage.
Using LeuM3 as a representative monocyte-specific anti-
gen, monocytes from 29 individuals with AIDS and ARC and
22 normal controls were subsequently compared for CD16 ex-
pression. A significantly higher percentage of LeuM3+ cells
from AIDS and ARC patients were CD 16+ when compared to
healthy donors (38.5±3.2% for AIDS vs. 10.4±1.0% for con-
trols; P < 0.0005) (Fig. 3). A similar incidence of CD16+,
CD14+ monocytes in the circulation of control subjects has
recently been demonstrated in other studies (6). Since both
ARC and AIDS patients exhibited CD16+ monocytes, no di-
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Figure 1. Expression of surface
CD16 (FcyRIII) on monocytes
from AIDS patients. MNL isolated
from blood ofthree control and
three AIDS patients were labeled
with FITC-3G8. After labeling,
cells were washed, fixed in 2%
paraformaldehyde and analyzed
by FMF with a FACStar Plus@.
rect correlation was apparent between CD 16 levels and clinical
status of the corresponding patients.
CD16 gene expression. MNL were further analyzed for the
presence of CD16-specific mRNA. Peripheral blood mono-
cytes from four AIDS patients and four control donors were
isolated by adherence for 1-2 h. Total cellular RNA was then
extracted and analyzed by Northern hybridization with the
CD 16 cDNA probe (23). As shown in Fig. 4, monocytes from
normal subjects (CJ-4) expressed little or no CD16-specific
mRNA, whereas mRNA from equivalent numbers of AIDS
patients' monocytes (AJ-4) was CD16 positive. Reprobing the
filters for constitutively expressed He7 revealed similar levels
in all eight lanes (not shown). These data are consistent with
previous observations that monocytes from healthy controls
express minimal or no CDl 6-specific mRNA (8), whereas the
monocytes from AIDS patients contain elevated levels of
CD16 steady-state mRNA.
Induction ofCD16 on normal monocytes by AIDS serum
andplasma. To identify potential mechanisms whereby mono-
cytes from HIV- 1-infected patients might be induced to ex-
press increased CD16 levels, serum and plasma from these pa-
tients were evaluated for soluble factors that could influence
monocyte CD 16 expression. Monocytes from normal individ-
uals were incubated with sera (10-20% in DME) from patients
and control subjects and analyzed by FMF for the appearance
of CD 16. After a 24-h incubation in the presence of serum
from AIDS patients, significantly increased levels ofCD16 ap-
peared on the control monocytes (Fig. 5). In contrast, sera from
control subjects did not significantly augment CD16 staining.
Subsequent experiments with plasma (to rule out the potential
contribution of factors released during the clotting process) re-
vealed that plasma samples from AIDS patients also induced
monocytes to express CD16 (Fig. 5). Based on these data, it
appears that a soluble factor(s) in the blood of AIDS patients
can induce monocyte expression ofCD 16.
Quantitation of TGF-3 in plasma ofAIDS patients. Since
TGF-,B has recently been shown to be capable of modulating
monocyte CD16 expression in vitro and in vivo (8, 9), addi-
tional studies addressed a potential role for this polypeptide
hormone in the constitutive expression ofCD 16 on peripheral
blood monocytes in AIDS patients. Plasma samples were as-
sayed for TGF-,B bioactivity before and after acid activation
(26), since TGF-,B in serum is normally bound to a2-macroglob-
ulin and biologically inactive (29). Plasma from patients con-
tained detectable TGF-,B bioactivity even without acid activa-
tion, but upon activation, the levels were dramatically in-
creased (Fig. 6, top). Thus, it appears that patients with AIDS
and/or ARC may have circulating levels of TGF-f, a propor-
tion of which is in the active form and furthermore, the levels
appear sufficient for induction of CD16 on monocytes (8, 9).
After having quantitated TGF-,B levels in the sera of patients
with AIDS, we attempted to correlate the levels of TGF-,3 with
the ability of the serum samples to induce CD16 on control
monocytes and with the incidence ofCD 16+ cells found in the
blood ofindividual subjects. As shown in Fig. 6 (bottom), there
was a direct correlation between quantifiable TGF-# levels in
control and patient sera and CD 16 induction on control mono-
cytes (r = 0.74, P < 0.001). Furthermore, a positive correlation
existed (r = 0.55, P 0.01) between serum TGF-,B levels and
the incidence ofCD 16+ cells in the circulation ofboth patients
and controls.
Inhibition ofplasma-inducedCDl6 expression by neutraliz-
ing antibody to TGF-f3. Because the data suggested that TGF-#
in AIDS patients' blood might influence CD16 expression on
Receptor FcyRIII on AIDS Peripheral Blood Monocytes 1775
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monocytes, plasma samples were pretreated with a neutralizing
antibody to TGF-# before being added to normal monocytes.
After 24 h, the cells were analyzed for CD16 expression. As
already demonstrated, plasma from AIDS patients induced a
Figure 2. Dual-color fluorescence profiles ofCD16 and
monocyte antigens. MNL were double-labeled with
FITC-3G8 and PE-conjugated antibodies for monocyte
antigens or with FITC-IgGI and PE-IgG2 for controls.
Shown are contour plots for monocyte populations from
a representative AIDS patient (top) and control subject
(bottom).
significant increase in CD16' monocytes (40-50%) compared
to plasma from healthy controls (< 10%) (Fig. 7). However, if
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Figure 3. CD16 expres-
sion on monocytes from
AIDS patients and con-
trols. Cells were labeled
and analyzed as in Figs.
* 1 and 2. Data represent
the percent LeuM3'
4 cells that are also CDl6
* positive for 22 control
-
and 29 AIDS/ARC sub-
:ontros jects.
occur when plasma samples were incubated with preimmune
IgG. For comparison, induction ofmonocyte CDl6 by recom-
binant TGF-f3 was also blocked with the antibody (Fig. 7).
Taken together, these data implicate TGF-fl in the blood of
AIDS patients as a mediator ofCDl6 expression on circulating
monocytes.
Discussion
In this study, we report that freshly isolated peripheral blood
monocytes from HIV-l-infected individuals express the gene
for FcyRIII (CD 16) and exhibit cell surfaceCD 16. Moreover, a
soluble factor in the blood of these patients induced CDl6
expression on monocytes from seronegative control individ-
uals. Inhibition of the AIDS plasma-derived CD 16-inducing
C1 C2
1.i .n
..,.x nON ,4.,YS'Ji;m
C3w. C4 ,*,
Figure 4. Northern hyl
RNA was extracted fro
A1 A2
60 - Figure 5. Augmentation
* PWaSMa ofCD16 by a plasma/
We50 0 Serum serum factor from AIDS
patients. Purified
40 % T monocytes (> 95%8
% * LeuM3+) from normal0
30 individuals were incu-
S 30 g * bated with sera (n = 7)
20 *or plasma (n = 8) (20%)from AIDS patients or
10 from control subjects
UO 10 _ g * | * for 24 h. The cells were
then labeled with FITC-
3G8 and analyzed by
AIDS Controls FMF for CD16 expres-
sion. Control mono-
cytes incubated with DME only were 12.4% Fc7RIII positive. Data
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with a 32P-labeled CDI6 cDNA probe.
activity with a neutralizing antibody to TGF-f implicated this
)olypeptide factor in the induction ofmonocyte CDl6 expres-
ion. As previously shown in vivo and in vitro, TGF-4 is a
otent mediator of CDl6 expression on a significant popula-
ion, although not all, peripheral blood monocytes (8, 9).
Whether a subpopulation ofmonocytes is particularly suscepti-
le to TGF-(3 up-regulation of CDl6 is unclear, although by
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trol monocytes. After
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lyzed by FMF. Data represent the mean of four different samples.
phenotypic analysis (Fig. 2), the CD1 6' monocytes express
common monocyte-specific antigens.
The expression of FcyR on the surface of monocytes and
other immune cells may play a critical role in the immuno-
pathogenesis of HIV infection. First, several laboratories have
recently demonstrated the existence ofHIV-specific antibodies
that enhance the infectivity ofHIV- 1 forbothT cells and mono-
cytes (10-12). This enhancing effect could be blocked by incu-
bating monocytes with monoclonal antibodies directed at
Fc'yRIII but not FcyRI, FcyRII, or the receptor for comple-
ment component 3 (10). Taken together, these data suggest
that FcyRIII on monocytes may mediate antibody-dependent
enhancement of HIV infectivity. Whether this mechanism is
independent of the CD4 protein, which is the normal route of
HIV internalization, is unknown since both abrogation and no
effect have been shown on the enhancement of infectivity after
treatment with anti-CD4 (30, 31). Although it is possible that
HIV- 1 can be internalized directly through FcyRIII, it is also
possible that IgG-sensitized viral particles binding to FcyRIII
facilitate the HIV- I-CD4 interaction.
Secondly, additional studies have shown that monocyte
functions mediated through FcyR are defective or abnormal in
patients with AIDS (32-35). However, there appeared to be no
correlation between functional defects and expression of these
surface receptors. For example, a defect in ADCC as well as in
the clearance of IgG-sensitized autologous erythrocytes from
the circulation of patients with AIDS has been reported (33).
Nevertheless, expression ofthe relevant FcyR was found to be
similar in both normal individuals and HIV-infected patients
(33-36). Elevated levels ofFcyRIII (CD 16) on AIDS monocyte
populations as compared to control monocytes have not
previously been reported, likely because the monocyte popula-
tions from controls and patients in earlier studies were main-
tained in culture, a procedure that induces differentiation and
CD 16 expression (7). Another possible explanation for this dis-
crepancy in phenotype and function is that the defect may
occur at the level of signal transduction or at some point later
in the activation pathway. However, in a recent study, it has
been reported that circulating LeuM3+/CD16+ monocytes are
less, rather than more, phagocytic than LeuM3+/CD 16-
cells (6).
Receptor-mediated clearance of IgG-opsonized microor-
ganisms and antigens is important in host defense (37, 38), and
its fluctuation may be deleterious in certain disease states. En-
hanced FcyR expression may, in fact, contribute to the patho-
genesis of certain diseases (36, 37-41). Immune complexes
and/or mononuclear cell-derived cytokines reportedly stimu-
late FcyR synthesis by circulating monocytes (42). Among
these cytokines, y-interferon and granulocyte/macrophage col-
ony-stimulating factor stimulate increased expression by hu-
man mononuclear phagocytes of FcyRI and FcyRII, respec-
tively (43, 44). Furthermore, in addition to TGF-f3 (8, 9)
Fc'yRIII expression on monocytic populations has also been
shown to be up-regulated by granulocyte/macrophage colony-
stimulating factor (45).
In addition to modulating FcyRIII expression, TGF-f is a
potent inhibitor ofimmunologic functions in vitro and in vivo
(25, 46-49), and it is possible that enhanced levels ofTGF-,3 in
patients with AIDS may also contribute to the immunosup-
pressed state of these individuals. T and B lymphocytes pro-
duce TGF-f3 when stimulated (50, 51), as do cells ofmonocyte
lineage (52-54). Moreover, infection ofperipheral blood mono-
cytes with HIV-1 in vitro results in augmented expression of
the gene encoding TGF-j3 (55) implicating this population as at
least one potential source of the elevated TFG-fl levels seen in
these patients. Identification of elevated levels of this potent
immunoregulatory cytokine in AIDS patients provides impor-
tant insight and avenues offurther investigation into the mech-
anisms of immune dysfunction in the acquired immunodefi-
ciency syndrome.
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